Ani Pharmaceuticals INC Form 4 insider transactions

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of Ani Pharmaceuticals Inc, sold 500 shares of common stock on August 13, 2026 for $75.48 per share.

Ori Gutwerg, SVP, GENERICS of Ani Pharmaceuticals Inc, sold 3,162 shares of common stock on August 10, 2026 for $77.00 per share.

Stephen P. Carey, SVP & CFO of Ani Pharmaceuticals Inc, sold 2,850 shares of common stock on July 29, 2026 for $81.36 per share.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of Ani Pharmaceuticals Inc, reported a transaction in 2,466 shares of common stock on July 18, 2026.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of Ani Pharmaceuticals Inc, sold 500 shares of common stock on July 13, 2026 for $81.84 per share.

ANI Pharmaceuticals SVP & CFO Stephen P. Carey executed a Rule 10b5-1 plan, exercising stock options and selling shares.

ANI Pharmaceuticals SVP & CFO Stephen P. Carey sold 2,850 shares of common stock valued at approximately $239,670, as part of a pre-arranged trading plan.

Meredith Cook, Senior VP and General Counsel at ANI Pharmaceuticals, sold 500 shares of common stock.

Director Jeanne Thoma acquired 4,357 shares of ANI Pharmaceuticals common stock via a restricted stock award.

ANI Pharmaceuticals director Renee P. Tannenbaum was granted 4,357 shares of common stock as a restricted stock award.

Director Antonio R. Pera acquired 4,357 shares of ANI Pharmaceuticals, Inc. common stock via a restricted stock award.

ANI Pharmaceuticals director Matthew J. Leonard was granted 4,357 shares of common stock via a restricted stock award.

ANI Pharmaceuticals Director Thomas Haughey reported a restricted stock award and a subsequent sale of 2,000 shares.

ANI Pharmaceuticals SVP & CFO Stephen P. Carey exercised options and sold 3,312 shares of common stock under a 10b5-1 plan.

ANI Pharmaceuticals Director Patrick D. Walsh sold 13,973 shares of common stock across two transactions in May 2026.

Thomas Andrew Rowland, SVP of ANI Pharmaceuticals, reported a sale of 459 shares of common stock on May 12, 2026.

Nikhil Lalwani, President & CEO and Director of ANI Pharmaceuticals Inc., reported a sale of 55,000 common shares.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, Inc., sold 500 shares of common stock on May 13, 2026, pursuant to a pre-established 10b5-1 trading plan.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, Inc., sold 500 shares of common stock on April 13, 2026, as part of a pre-arranged trading plan.

ANI Pharmaceuticals' SVP, Thomas Rowland, sold 4,772 shares of common stock for $74.91 per share under a pre-arranged trading plan.

Christopher Mutz, ANI Pharmaceuticals' Head of Rare Disease, sold 3,162 shares of common stock for a weighted average price of $71.64 per share.

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals, sold 500 shares of common stock for $72.62 per share.

ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, has reported planned transactions for March 5, 2026, involving the exercise of stock options and subsequent sale of common stock under a Rule 10b5-1 plan.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, sold 417 shares of common stock for $74 each under a pre-arranged trading plan.

Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals, sold 2,060 shares of common stock for $76.50 per share.

ANI Pharmaceuticals Director Patrick D. Walsh sold 6,000 shares of common stock for $74.23 per share under a pre-arranged trading plan.

ANI Pharmaceuticals' Head of R&D and COO-Novitium Ops, Muthusamy Shanmugam, was granted 11,116 restricted common shares valued at $77.15 per share.

ANI Pharmaceuticals SVP Thomas Rowland received a restricted stock award and had shares withheld for tax purposes.

ANI Pharmaceuticals' Head of Rare Disease, Christopher Mutz, received a restricted stock award and had shares withheld for tax purposes.

ANI Pharmaceuticals CEO Nikhil Lalwani was granted 75,592 shares of common stock as a restricted stock award, increasing his direct beneficial ownership.